Association in Medical Technology

SCAI Statement on the BARI 2D Trial (Bypass Angioplasty Revascularization Investigation With Diabetes Trial) Presented at the American Diabetes Association (ADA) Annual Scientific Sessions and Published in The New England Journal of Medicine

WASHINGTON, June 7 /PRNewswire/ -- BARI-2D is a useful and focused trial that builds on the body of scientific knowledge physicians use to provide the best possible care for diabetic patients with chronic stable angina and to evaluate their treatment options. The Society for Cardiovascular Angiog...

InteKrin Therapeutics to Present at the 2009 American Diabetes Association Annual Meeting

LOS ALTOS, Calif., May 28 /PRNewswire/ -- InteKrin Therapeutics, Inc. announced today it will present Phase 2a clinical data for INT131, a Selective PPAR Modulator (SPPARM), at the American Diabetes Association annual meeting in New Orleans Saturday, June 6, 2009 during the "Novel Diabetes Therapi...

Ridge Diagnostics, Inc. Clinical Data on Blood Test for Depression Presented at American Psychiatric Association Annual Meeting

SAN DIEGO, May 20 /PRNewswire/ -- Ridge Diagnostics, Inc., a neurodiagnostic company, announced that data from clinical studies for its first-in-class, proprietary blood test for Major Depressive Disorder(MDD), will be presented during a poster session entitled Multianalyte Biomarker Blood Test...

ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the Association for Research in Vision and Ophthalmology (ARVO) 2009 Annual Meeting

FT. LAUDERDALE, Fla., May 7 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA ), today presented results from the Company's Bepreve(TM) (bepotastine besilate ophthalmic solution) Phase 3 pivotal clinical studies using the Conjunctival Allergen Challenge (CAC) model of allergic c...

Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology 2009 Meeting

- Presentation describes Palomid 529 as a first-in-class Dual TORC1/TORC2 complex inhibitor of the PI3K/Akt/mTOR pathway showing efficacy in retinal scarring caused by retinal detachment - JAMAICA PLAIN, Mass., May 6 /PRNewswire/ -- Paloma Pharmaceuticals, Inc. presented "Palomid 529, An Inhi...

American Lung Association Offers Simple Tips to Protect Public Health and Minimize H1N1 Flu (Swine Flu) and Seasonal Flu Transmission

WASHINGTON, May 4 /PRNewswire-USNewswire/ -- As the confirmed number of H1N1 Flu (Swine Flu) cases grows in the United States, public concern understandably grows. The American Lung Association wishes to ease public concern by offering proven advice on how to prevent the spread of contagious respi...

Sirion Therapeutics Announces Clinical Data Presentations at the 2009 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

TAMPA, Fla., April 30 /PRNewswire/ -- Sirion Therapeutics, Inc. announced today that eight presentations related to the Company's products, pipeline and research will be presented at the 2009 annual meeting of The Association for Research in Vision and Ophthalmology (ARVO) in Ft. Lauderdale, FL. ...

Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting

Final results from three large PEGINTRON(TM) clinical studies address key questions in the treatment of hepatitis C COPENHAGEN, Denmark, April 27 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ) today reported that final results of three large PEGINTRON(TM) (peginterferon ...

InterMune Reports Presentation of Triple Combination Study of ITMN-191 at European Association for the Study of the Liver (EASL)

- Results inform selection of doses, regimens to be explored in Phase 2b study - -- Phase 2b program anticipated to begin in summer 2009 -- COPENHAGEN , April 24 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN ) today announced that results from a 14-day Phase 1b clinical stu...

Trubion Pharmaceuticals, Inc. Announces Upcoming Presentation at the 2009 American Association of Cancer Research Annual Meeting

SEATTLE, April 16 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN ) announced today that it will present data regarding its SCORPION(TM) multispecific therapeutic technology at the 100th Annual Meeting of the American Association of Cancer Research (AACR) in Denver, April 1...

Cequent tkRNAi Technology to be Presented at the Centennial Meeting of the American Association for Cancer Research

Monday poster honored with special recognition awarded to top-rated abstracts CAMBRIDGE, Mass., April 15 /PRNewswire/ -- Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, announced that the company's Trans...

American Lung Association Study to be Published in the 'New England Journal of Medicine' Finds Prescription Heartburn Medication Does Not Control Asthma Symptoms as Previously Thought

--Practice Changing Study Calls on Doctors to Stop Prescribing Potent Heartburn Medications to Asthma Patients Without Frequent Symptoms of Gastric Reflux-- WASHINGTON, April 8 /PRNewswire-USNewswire/ -- For nearly 20 years, it was believed that severe asthma symptoms such as coughing, wheezi...

BARC Central Laboratory Joins Alzheimer's Association Research Roundtable

- Global Laboratory's Technology Transfer Expertise to Support Biomarker Translational Research - NEW YORK, March 30 /PRNewswire/ -- Biomarkers have become increasingly important to Alzheimer's disease research as a method for risk assessment, early detection, testing new therapies and eventu...

Joint Statement from the American Diabetes Association and American Association of Clinical Endocrinologists on the NICE-SUGAR Study on Intensive Versus Conventional Glucose Control in Critically Ill Patients

Response to March 24 article in the New England Journal of Medicine ALEXANDRIA, Va. and JACKSONVILLE, Fla., March 24 /PRNewswire-USNewswire/ -- A study published online today in the New England Journal of Medicine suggests that intensive blood glucose (sugar) control for critical ...

YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB PRESENTATIONS TO BE MADE AT THE 100TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH AND EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY

MISSISSAUGA, ON, March 13 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Alternext US:YMI, TSX:YM, AIM:YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today reported that its poster entitled, "Binding properties of the ant...

American Heart Association EMS Survey Uncovers Deficiencies in Response, Treatment and Transfer of Patients With Most Deadly Heart Attacks

Association's Mission: Lifeline initiative to use survey data to make improvements DALLAS, Feb. 16 /PRNewswire-USNewswire/ -- Preliminary results of one of the nation's largest national surveys of Emergency Medical Services (EMS) systems indicate the need for improvements in the way heart att...

American Lung Association Celebrates 101st Annual Christmas Seals Campaign

Visit www.christmasseals.org to learn more, make a donation or send a Christmas Seals e-card WASHINGTON, Nov. 17 /PRNewswire-USNewswire/ -- Millions will receive Christmas Seals in the mail this month, courtesy of the American Lung Association. These decorative holiday stamps are part o...

Celladon Announces Presentation of Clinical Data From First-in-Human MYDICAR(R) Trial for Advanced Heart Failure at American Heart Association Scientific Sessions

Phase 1 Data Demonstrate Safety and Improvement in Heart Failure in a Majority of Patients NEW ORLEANS, Nov. 9 /PRNewswire/ -- Celladon Corporation announced today results from the first nine patients treated with MYDICAR(R), a genetically-targeted enzyme replacement ...

Portola Announces Data Presentations Relevant to Its Lead Phase II Antithrombotic Compounds at American Heart Association Scientific Sessions 2008

SOUTH SAN FRANCISCO, Calif., Nov. 6 /PRNewswire/ -- Portola Pharmaceuticals, a biopharmaceutical company developing innovative drugs that provide significant advances in cardiovascular and inflammatory diseases, and cancer, today announced that data relevant to betrixaban, the company's novel ...

Alzheimer's Association Grant Furthers Successful Research at UMass Lowell

'SmartPill' Uses Vitamin Formulation to Improve Brain Health, Memory LOWELL, Mass., Oct. 24 /PRNewswire-USNewswire/ -- Researchers at UMass Lowell have demonstrated success in improving the memory and brain function of patients with Alzheimer's disease, findings that will be published in the...

Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting

PLYMOUTH MEETING, Pa., Oct. 6 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR ) today reported data from its second Phase 1 clinical trial of trodusquemine (MSI-1436), Genaera's lead drug candidate for the treatment of type 2 diabetes and obesity. MSI-1436 is a novel inhibitor of ...

American Heart Association Scientific Statement: Heart Patients Should Be Screened, Treated for Depression

Studies show that depression is about three times more common in patients following a heart attack than in the general community. Heart patients should be screened for depression, and treated if necessary. DALLAS, Sept. 30 /PRNewswire-USNewswire/ -- Heart patients should be screened for de...

American Heart Association Journal Report: Miniaturized Heart Pumps May Be Effective for Children Awaiting Transplant

Study highlights: In a small study, miniaturized heart pumps helped keep children alive who were awaiting a heart transplant. The devices are not approved for general use in the United States. DALLAS, Sept. 30 /PRNewswire-USNewswire/ -- In a recent study, nine pediatric patients with sev...

American Heart Association Journal Report: Surgical Residents Perform Heart Surgery as Effectively as Staff Surgeons

Study highlights: * Success rates, safety and long-term outcomes of heart surgery are not significantly different when performed by properly supervised surgical residents or staff surgeons. * It is safe to include the training of residents even in complex procedures. It is critical that tr...

Parents Make Donations to National Autism Association for Cutting-Edge Research

NIXA, Mo., Sept. 25 /PRNewswire-USNewswire/ -- The National Autism Association (NAA) has recently received generous donations totaling $30,000 for its Progress Research Fund from fellow parents within the autism community. NAA expresses its sincere gratitude to Bruce and Kelly Vanicek for th...

Palatin Technologies Presents PL-3994 Clinical Trial Results at the 12th Annual Scientific Meeting of the Heart Failure Association of America

CRANBURY, N.J., Sept. 23 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (Amex: PTN ) announced it presented results from a Phase 1 clinical study with PL-3994, a novel, long-acting natriuretic peptide receptor A (NPRA) agonist under development for treatment of the chronic treatment of ...

MedNet Solutions to Sponsor and Exhibit at the 2008 Advanced Medical Technology Association Conference in Washington, D.C.

MINNETONKA, Minn., Sept. 18 /PRNewswire/ -- MedNet Solutions, a global eClinical technology company specializing in clinical study management systems, today announced the company's active involvement as a sponsor and exhibitor at the 2008 Advanced Medical Technology Association (AdvaMed) MedTe...

VIA Pharmaceuticals to Present at American Heart Association Scientific Sessions 2008

Topline Data from Phase 2 CEA and ACS Clinical Trials to be Released Concurrent with AHA Presentation SAN FRANCISCO, Sept. 15 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP ), a biotechnology company focused on the development of compounds for the treat...

American Lung Association Study Finds No Evidence of Depression or Suicide Linked to Asthma and Allergy Drug Montelukast

WASHINGTON, Sept. 1 /PRNewswire-USNewswire/ -- There has been recent concern that suicide may be a complication of montelukast (Singulair) therapy. Montelukast is a Food and Drug Administration (FDA) approved oral drug that has been prescribed for more than a decade for the treatment of asthma...

Journal of the American Dental Association Publishes Key Clinical Data for the Use of OraVerse(TM) a Local Anesthetic Reversal Agent

SAN DIEGO, Aug. 12 /PRNewswire/ -- Novalar Pharmaceuticals, Inc., a dental specialty pharmaceutical company, announced the publication of three clinical trials on the use of OraVerse (phentolamine mesylate) injection as a local dental anesthetic reversal agent in the August 2008 issue of the J...

VAP Cholesterol Test Helps Reveal Association Between Adiponectin Levels and Atherosclerosis

Detailed lipid profile helps clinicians identify risk in patients, including non-diabetics, despite normal LDL levels and statin therapy BIRMINGHAM, Ala., July 21 /PRNewswire/ -- Using the VAP Cholesterol Test from Atherotech, researchers have identified a link between adiponectin and he...

Kendle Experts to Present at the Drug Information Association 44th Annual Meeting

CINCINNATI, June 19 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL ), a leading global full-service clinical research organization (CRO), today announced that several of its experts will present at the upcoming Drug Information Association (DIA) 44th Annual Meeting. The meeting is scheduled f...

Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting

Presentation Details Statistically Significant and Clinically Relevant Results for SB-509 in Development for Treatment of Diabetic Neuropathy SAN FRANCISCO, June 8 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO ) announced today the presentation of encouraging Phase 1b ...

CNS Response, Inc. Provides Review of Poster Session Delivered at the American Psychiatric Association 161st Annual Meeting

Preliminary Analysis of rEEG(R) Guided Medication Study Demonstrates an Improvement in Depression and Eating Disorder Symptoms COSTA MESA, Calif., May 22 /PRNewswire-FirstCall/ -- CNS Response, Inc. (OTC Bulletin Board: CNSO) reported today the results of a study presented at the Ameri...

Cryoablation Is Focus of 17 Clinical Studies at American Urological Association Annual Meeting

M.D. Anderson, Cleveland Clinic Among Group of Leading Cancer Centers Presenting Cryoablation Data IRVINE, Calif., May 21 /PRNewswire-FirstCall/ -- Endocare, Inc. (Nasdaq: ENDO ), an innovative medical device company focused on the development of minimally invasive techn...

Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting

Efficacy and safety data support potential of asenapine in the treatment of schizophrenia and bipolar I disorder WASHINGTON, May 8 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ) today announced that an overview of asenapine clinical trials from the Olympia p...

Data Presented at the American Psychiatric Association (APA) Annual Meeting Demonstrate Iloperidone's Efficacy and Safety, With Low Rates of Movement and Metabolic Adverse Events

Pharmacogenetic Findings May Lead to Individualized Treatment for Schizophrenia WASHINGTON, MAY 6 /PRNewswire-FirstCall/ -- Data presented today on Vanda Pharmaceuticals Inc.'s (Nasdaq: VNDA ) investigational drug candidate, iloperidone, included its 4-week, sho...

Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting

MOUNTAIN VIEW, Calif., May 1 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today that it will present at the 161st American Psychiatric Association annual meeting the results of a Phase 2a clinical trial of Staccato(R) loxapine (AZ-004) for the treatment of ...

Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting

PHILADELPHIA, May 1 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced today that it will present key scientific data on its Attention Deficit Hyperactivity Disorder (ADHD) treatments, lisdexamfetamine dimesylate, methylphen...

Dr. Calvin Grant Presents Results from Xibrom(TM) Combination Therapy with Lucentis(R) at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO)

TAMPA, Fla., April 27 /PRNewswire-FirstCall/ -- Calvin A. Grant, MD, Retina Macular Care, presented the results from his 60-patient retrospective case control study that was designed to evaluate the adjuvant use of Xibrom(TM) (bromfenac 0.09mg ophthalmic solution) in Lucentis(R) (ranibizumab) ...